Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Phase 3 TRIUMPH Program (Ongoing) - LIVER AS SECONDARY ENDPOINT Status: Currently ongoing, results expected 2026 TRIUMPH-4 (Completed December 2025): Primary endpoints: Weight loss + osteoarthritis pain Results: 28.7% weight loss at 68 weeks Liver outcomes: Secondary/exploratory endpoints TRIUMPH-2 (Ongoing, expected 2026): Weight loss in obesity + type 2 diabetes Liver outcomes: Secondary endpoints (liver enzymes, possibly imaging) Key Point: TRIUMPH Phase 3 trials are NOT primarily liver-focused
Common complaints No pharmacy is perfect, and Strive has its share of negative reviews
Significant reduction in all-cause mortality with Ozempic 1 For adults with T2D and CKD for a confirmatory secondary endpoint: time to first occurrence of all-cause mortality vs placebo when both were added to standard of care 1,2 All cause death 1-3 1-3 cc 2.5% ARR reported at 3 years in pre-specified supplementary analysis
After reaching therapeutic doses (0.5 to 1.0 mg weekly), the same individuals typically consumed 1,500 to 1,900 calories per day while reporting high satisfaction and no feelings of deprivation
It is important to note that energy levels and motivation are influenced by multiple factors, including diet, sleep quality, physical activity, mental health, and underlying medical conditions
US$ 28.39
US$ 20.63
US$ 22.96
US$ 24.90
